Delgocitinib is a JAK inhibitor that blocks the activation of the JAK-STAT pathway which has been shown to play a key role in the pathophysiology of chronic inflammatory skin diseases.

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

and 50.4 percent of those with one and two or more moderate risk factors were recommended aspirin prophylaxis.

HealthDay News — More than 100,000 Rich’s Ice Cream Co. bars have been recalled due to possible listeria contamination. The affected ice cream bars were sold across 23 states and in Nassau, capital of ...

The first recall affects tuna salad and ready-to-eat foods containing tuna salad from Beaverton, Oregon-based Reser's Fine Foods.

HealthDay News — The US Food and Drug Administration has appointed George Francis Tidmarsh, MD, PhD, as director of the Center for Drug Evaluation and Research (CDER).

The ABTECT clinical program included the randomized, double-blind, placebo-controlled phase 3 ABTECT-1 and ABTECT-2 trials.

In addition to oral administration, Spritam may now be administered via nasogastric tube (NG tube) or gastrostomy tube (G tube). The approval was based on data confirming that the drug can be ...

Older age, Black race, very low Child Opportunity Index, public insurance linked to lower rates of nirsevimab receipt ...

Researchers recommended that regulators consider mandating head-to-head trials comparing next-in-class and against existing in-class agents when possible.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

HealthDay News — The US Department of Health and Human Services has announced a major initiative to reform the organ transplant system. This action follows an investigation by the Health Resources and ...